However, patients terminating BRAF ± MEKi in this retrospective study for other reasons than PD showed a higher rate of tumor progression (69.2%) and a shorter PFS upon termination of TT, which might be explained by the longer overall observation period covered in our study [22,34,35]. This evidence concerns the gene BRAF and neoplasm.